Treatment of Prostate Cancer with a DBP-MAF-Vitamin D Complex to Target Angiogenesis and Tumorigenesis
Abstract
The purpose of this study has been to determine the efficacy of combined therapy using vitamin D binding protein-macrophage activating factor (DBP-maf) and vitamin D as therapy for prostate cancer using a mouse model of human prostate tumors. In this phase of the study we have tested the ability of vitamin D and DBP-maf to inhibit the formation of endothelial cells into tubes. Both molecules were effective on their own, however, the combination of vitamin D and DBP-maf showed synergistic behavior. Because of its high affinity for actin, the possibility that DBP-maf acted by inhibiting microtubule formation was investigated using an anti-phalloidin antibody. No differences in phalloidin strength or localization were observed. Using immunoassays we were able to identify a 75 kDa protein in tumor cells that is phosphorylated by DBP-maf and a synthetic maf peptide. We are investigating the identity of that protein since the mechanism by which DBP-maf works remains unknown.
Document Details
- Document Type
- Technical Report
- Publication Date
- Feb 01, 2007
- Accession Number
- ADA477038
Entities
People
- Michael W. Fannon
Organizations
- University of Kentucky